A safety profile of medications used to treat Waldenström’s macroglobulinemia-Reference-Cited by-同舟云学术

A safety profile of medications used to treat Waldenström’s macroglobulinemia

Published:2018-06-03 Issue:6 Volume:17 Page:609-621
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

García-Sanz Ramón¹^ORCID,Jiménez Cristina¹,González De La Calle Verónica¹^ORCID,Sarasquete María Eugenia¹^ORCID

Affiliation:

1. Servicio de Hematología, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer de Salamanca, CIBERONC, Salamanca, Spain

Funder

Gilead Sciences

Instituto de Salud Carlos III

Miguel Servet Programme

Beca de investigación FEHH-CRIS 2018

Asociación Castellano-Leonesa de Hematología y Hemoterapia

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2018.1477936

Reference102 articles.

1. The 2016 revision of the World Health Organization classification of lymphoid neoplasms

2. MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

3. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia

4. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database

5. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology;Recent Patents on Anti-Cancer Drug Discovery;2020-12-29